ArticlePigment cell & melanoma research2017
Kinase gene fusions in defined subsets of melanoma.
Article in Pigment cell & melanoma research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Pooled it
- Comprehensive genomic profiling of mucosal melanoma reveals novel fusion transcripts and dysregulation of cell-cycle, MAPK, and PI3K pathways.The Journal of pathology · 2026Article
- Profiling Serum Oxylipin Metabolites Across Melanoma Subtypes and Immunotherapy Responders.Metabolites · 2025Article
- Evaluating Gene Fusions as Prognostic Biomarkers and Therapeutic Targets in Immune Checkpoint Blockade-Treated Advanced Melanoma: A Retrospective Analysis.Cancer research communications · 2025Article
- Expanding the landscape of oncogenic drivers and treatment options in acral and mucosal melanomas by targeted genomic profiling.International journal of cancer · 2024Article
- Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.BMC cancer · 2023Article
- Prognostic value and immune infiltration of ARMC10 in pancreatic adenocarcinoma via integrated bioinformatics analyses.Heliyon · 2023Article
- Clinical features, molecular pathology, and immune microenvironmental characteristics of acral melanoma.Journal of translational medicine · 2022Review
- Case report: complete remission with crizotinib inFrontiers in oncology · 2022Article
- Melanoma Targeted Therapies beyondCancers · 2021Review
- Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.Nature communications · 2021Article
- Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- The tumor genetics of acral melanoma: What should a dermatologist know?JAAD international · 2020Article
- Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives.Cancers · 2020Review
- Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- PS4DR: a multimodal workflow for identification and prioritization of drugs based on pathway signatures.BMC bioinformatics · 2020Article
- The mutational landscape of mucosal melanoma.Seminars in cancer biology · 2020Review
- Overcoming Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutated Tumours.Journal of oncology · 2020Review
- Aberrant DNA Methylation Predicts Melanoma-Specific Survival in Patients with Acral Melanoma.Cancers · 2019Article
- Targeted Genomic Profiling of Acral Melanoma.Journal of the National Cancer Institute · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
Genomic rearrangements resulting in activating kinase fusions have been increasingly described in a number of cancers including malignant melanoma, but their frequency in specific melanoma subtypes has not been reported. We used break-apart fluorescence in situ hybridization (FISH) to identify genomic rearrangements in tissues from 59 patients with various types of malignant melanoma including acral lentiginous, mucosal, superficial spreading, and nodular. We identified four genomic rearrangements involving the genes BRAF, RET, and ROS1. Of these, three were confirmed by Immunohistochemistry (IHC) or sequencing and one was found to be an ARMC10-BRAF fusion that has not been previously reported in melanoma. These fusions occurred in different subtypes of melanoma but all in tumors lacking known driver mutations. Our data suggest gene fusions are more common than previously thought and should be further explored particularly in melanomas lacking known driver mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.